Evaluating novel diagnostics and enabling preventive measures for childhood tuberculosis between the UK and partners in Sub-Saharan Africa
Evaluating novel diagnostics and enabling preventive measures for childhood tuberculosis between the UK and partners in Sub-Saharan Africa
批准号:
MC_EX_MR/P024270/1
负责人:
Beate Kampmann
金额:
$79.09万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2017
资助国家:
英国
项目状态:
已结题
起止时间:
2017 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This project aims to develop and validate better diagnostic tools for children with TB (Find and Treat), as well as looking at implementation of preventive therapy for those already infected but not yet ill, but who might progress to disease if not receiving the recommended intervention- (Screen and Prevent).Importance of TB in LMIC:Around 1 million children fall ill from TB each year and 140 000 die. Many countries struggle to deliver the age-stratified notifications for TB in children to the WHO, and there is reluctance to engage in diagnosing and treating TB in children in many settings, as staff feel ill equipped to confirm a "gold standard" diagnosis, based on microbiological evidence. This situation is pertinent in Africa and continues to lead to unnecessary morbidity and mortality and a reservoir of cases for the future. The roadmap for the elimination of TB sets priorities for achieving global TB control and within this effort, childhood TB has been identified as a neglected problem, but of great importance for overall TB control (WHO Global Plan for TB).This requires two interventions: 1. to appropriately diagnose the cases and place on treatment -find and treat- and 2. to prevent secondary cases in TB-exposed children, which can be done successfully by delivering preventive medication- screen and prevent.Why is it more difficult to diagnose TB in children?Due to the limited number of mycobacteria contained in their sputa, conventional microbiological diagnostics perform poorly in children. Unless more sensitive diagnostics for paucibacillary disease can be developed, it is unlikely that the current situation of two thirds of children receiving treatment for TB without a confirmed diagnosis will change. Host-derived biosignatures in blood or urine therefore hold promise for development into point-of care tests for childhood TB.What do we want to do?We have considerable experience in the management of childhood TB in both the UK and The Gambia, and this project aims to involve new partners in Africa to find and treat children with TB using existing and new diagnostics. We have already developed such new tests but they need to be further validate also in children who have HIV or malnutrition. We will therefor recruit a large prospective court of children likely o have TB to validate the new diagnostics.In addition, we want to work the National TB programs (NTP) in the partner countries to implement a preventive strategy, as supported by the WHO but not implemented on the ground. We want to understand the bottlenecks within the care path and train members of the NTP to recognise TB in children and take the necessary preventive steps to avoid secondary cases in families. Based on the UK model, we have already established a screen-and-prevent- program of contact screening for children exposed to TB in their households in The Gambia, which has the support of the NTP. Our find and treat and screen and prevent activities have increased the case notifications by 50% over the last 3 years. This approach now requires full integration into the NTP programs in other countries and systematic evaluation to determine its long term impact on national TB figures also in our partner countries. It could serve as an important model for the WHO strategy o improve prevention of TB worldwide but each country might have specific requirements and our project will deliver data from 4 different African settings to inform the recommendations.We expect that our work can improve TB control and that we can create a network of excellence with specialist knowledge for childhood TB in Africa, as we have already done in Europe.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.vaccine.2019.11.060
发表时间:
2020-02-24
期刊:
Vaccine
影响因子:
5.5
作者:
[Angelidou A, Conti MG, Diray-Arce J, Benn CS, Shann F, Netea MG, Liu M, Potluri LP, Sanchez-Schmitz G, Husson R, Ozonoff A, Kampmann B, van Haren SD, Levy O]
通讯作者:
Levy O
DOI:
10.1016/s1473-3099(18)30157-9
发表时间:
2019-03
期刊:
The Lancet. Infectious diseases
影响因子:
--
作者:
[Basu Roy R, Whittaker E, Seddon JA, Kampmann B]
通讯作者:
Kampmann B
DOI:
10.3389/fgene.2018.00457
发表时间:
2018
期刊:
Frontiers in genetics
影响因子:
3.7
作者:
[Bah SY, Forster T, Dickinson P, Kampmann B, Ghazal P]
通讯作者:
Ghazal P
Conducting clinical research in a resource-constrained setting: lessons from a longitudinal cohort study in The Gambia.
在资源受限的环境中进行临床研究:冈比亚纵向队列研究的教训。
DOI:
10.1136/bmjgh-2021-006419
发表时间:
2021-08
期刊:
BMJ global health
影响因子:
8.1
作者:
[Imam A, Wariri O, Dibbasey T, Camara A, Mendy A, Sanyang AN, Ceesay M, Jallow S, Jallow AE, Bah K, Johnson N, Trawally E, Sowe D, Darboe A, Kampmann B, Idoko OT]
通讯作者:
Idoko OT
In reply.
回复。
DOI:
10.3949/ccjm.81c.12002
发表时间:
2014
期刊:
Cleveland Clinic journal of medicine
影响因子:
6.1
作者:
[ChingSun,GraceE, Kashyap,SangeetaR, Nasr,Christian]
通讯作者:
Nasr,Christian
Immunising Pregnant women and infants network- IMPRINT
-
批准号:MR/Y033752/1
-
项目类别:Research Grant
-
资助金额:$161.24万
-
财政年份:2023
-
负责人:Beate Kampmann
-
依托单位:
Thematic Support - Vaccines and Immunity
-
批准号:MC_UU_00031/2
-
项目类别:Intramural
-
资助金额:$317.7万
-
财政年份:2022
-
负责人:Beate Kampmann
-
依托单位:
IMPRINT: IMmunising PRegnant women and INfants neTwork
-
批准号:MR/R005990/2
-
项目类别:Research Grant
-
资助金额:$286.67万
-
财政年份:2018
-
负责人:Beate Kampmann
-
依托单位:
IMPRINT: IMmunising PRegnant women and INfants neTwork
-
批准号:MC_PC_17221
-
项目类别:Intramural
-
资助金额:$76.44万
-
财政年份:2018
-
负责人:Beate Kampmann
-
依托单位:
IMPRINT: IMmunising PRegnant women and INfants neTwork
-
批准号:MR/R005990/1
-
项目类别:Research Grant
-
资助金额:$246.1万
-
财政年份:2017
-
负责人:Beate Kampmann
-
依托单位:
Childhood tuberculosis: Integrating tools for improved diagnosis and vaccines
-
批准号:MC_EX_MR/K011944/1
-
项目类别:Research Grant
-
资助金额:$254.84万
-
财政年份:2013
-
负责人:Beate Kampmann
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: